Web Analytics Made Easy - Statcounter

top of page

Chemotherapy Protocols

Myeloma clinical trials.jpg

MYELOMA CLINICAL TRIALS

Multiple Myeloma Patient Education.jpg

Multiple Myeloma Patient Education

Home
Trials
FAQ
Drugs
- Treatment Agents
- FDA
Centers
Events
About us
More

Use tab to navigate through the menu items.

NCT05427812: Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma

Recruiting

Dec 1, 2022

1 min read

Updated: Feb 4, 2024

Tags:

United States
Australia
- New York: Tisch Cancer Institute Mount Sinai Hospital New York
Ichnos Sciences SA
ISB 1442

Recruiting
Relapsed & Refractory MM
Phase 1/2

Posts Archive

December 2023 5 posts
December 2022 76 posts
December 2021 71 posts
August 2021 12 posts
June 2021 49 posts
December 2020 87 posts
December 2019 76 posts
December 2018 69 posts
December 2017 55 posts
December 2016 37 posts
December 2015 30 posts
December 2014 27 posts
December 2013 18 posts
December 2012 14 posts
December 2011 8 posts
December 2010 14 posts
December 2009 6 posts
December 2008 7 posts
December 2007 14 posts
December 2006 4 posts
December 2005 3 posts
December 2004 5 posts
December 2003 3 posts
December 2002 2 posts
December 2000 4 posts

Trials: NDMM RRMM MGUS/SMM
Phase 3 Phase 2 Phase 1/2 Phase 1
MCT Tags CART Trials

About us Contact us
Myeloma Centers Events

MCT-Myeloma Clinical Trials LLC
445 Park Avenue, 9th Floor
New York, NY, 10022
Tel: 1-212-634-7914
contact@mmeducation.org

© 2022 MCT-Myeloma Clinical Trials LLC

bottom of page